Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aclaris Therapeutics Inc (ACRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ACRS (5-star) is a WEAK-BUY. BUY since 18 days. Profits (-11.80%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
6 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $8.17
Year Target Price $8.17
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 63% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 159.17M USD | Price to earnings Ratio - | 1Y Target Price 8.17 |
Price to earnings Ratio - | 1Y Target Price 8.17 | ||
Volume (30-day avg) 6 | Beta 0.42 | 52 Weeks Range 1.05 - 5.17 | Updated Date 06/30/2025 |
52 Weeks Range 1.05 - 5.17 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-06-06 | When Before Market | Estimate -0.29 | Actual -0.12 |
Profitability
Profit Margin - | Operating Margin (TTM) -1222.27% |
Management Effectiveness
Return on Assets (TTM) -18.2% | Return on Equity (TTM) -91.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37786390 | Price to Sales(TTM) 8.95 |
Enterprise Value 37786390 | Price to Sales(TTM) 8.95 | ||
Enterprise Value to Revenue 2.13 | Enterprise Value to EBITDA 0.28 | Shares Outstanding 108281000 | Shares Floating 67057489 |
Shares Outstanding 108281000 | Shares Floating 67057489 | ||
Percent Insiders 2.69 | Percent Institutions 88.26 |
Analyst Ratings
Rating 3 | Target Price 8.17 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aclaris Therapeutics Inc
Company Overview
History and Background
Aclaris Therapeutics, Inc. (ARRS) is a pharmaceutical company focused on developing novel treatments for immuno-inflammatory diseases. Founded in 2012, it went public in 2015. Initially, it focused on dermatology but has expanded its scope to include broader immuno-inflammatory conditions.
Core Business Areas
- Immuno-inflammatory Disease Therapeutics: Aclaris focuses on developing and commercializing small molecule and biologic therapies for immuno-inflammatory diseases, including skin diseases and other inflammatory conditions.
- Contract Research: Aclaris also provides contract research services for dermatological and other treatments.
Leadership and Structure
Dr. Neal Walker is the CEO and President. The company has a typical corporate structure with a board of directors and various executive leadership positions overseeing different functional areas.
Top Products and Market Share
Key Offerings
- Zunrepath (ATI-1777): A JAK1/3 inhibitor being developed for the treatment of rheumatoid arthritis. Market share data is currently unavailable as the product is still in development. Competitors include larger pharmaceutical companies such as AbbVie and Pfizer who produce products such as Rinvoq and Xeljanz.
- ATI-450: A MK2 inhibitor. This is in development for immuno-inflammatory diseases such as rheumatoid arthritis. Market share data is not currently available as it is still in development. Competitors include larger pharmaceutical companies such as AbbVie and Pfizer who produce products such as Rinvoq and Xeljanz.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with significant regulatory hurdles. The immuno-inflammatory disease market is substantial and growing, driven by aging populations and increased disease prevalence.
Positioning
Aclaris is positioned as a specialty pharmaceutical company focused on niche markets within the immuno-inflammatory disease space. Its competitive advantage lies in its innovative drug development pipeline and targeted approach to unmet medical needs.
Total Addressable Market (TAM)
The global immuno-inflammatory drugs market is expected to reach hundreds of billions of dollars. Aclaris is positioned to capture a portion of this market through its pipeline of novel therapies. An exact TAM that Aclaris could expect is hard to know until the product is finalized and goes to market.
Upturn SWOT Analysis
Strengths
- Innovative drug development pipeline
- Focus on unmet medical needs
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trials
- Limited commercial infrastructure compared to larger pharmaceutical companies
- Financial dependence on fundraising and partnerships
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or companies
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory challenges
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- PFE
- BMY
Competitive Landscape
Aclaris faces intense competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its innovative pipeline and focus on niche markets, but it must overcome challenges related to funding and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by pipeline development and strategic partnerships. Aclaris hasn't achieved significant revenue growth yet due to its pipeline's stage.
Future Projections: Future growth depends on the successful development and commercialization of its pipeline assets. Analyst estimates vary widely based on clinical trial outcomes. There are no revenue targets known.
Recent Initiatives: Recent initiatives include advancing Zunrepath and ATI-450 through clinical trials and seeking strategic partnerships.
Summary
Aclaris Therapeutics is a pharmaceutical company with a promising pipeline of immuno-inflammatory disease treatments, but it faces significant risks due to its reliance on clinical trial success and limited financial resources. Its innovative approach and focus on unmet medical needs provide opportunities for growth, but competition from larger players and regulatory hurdles present considerable challenges. The company's future depends on effectively navigating these challenges and successfully commercializing its pipeline assets. Clinical Trials for Zunrepath and ATI-450 may change the company's standing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclaris Therapeutics Inc
Exchange NASDAQ | Headquaters Wayne, PA, United States | ||
IPO Launch date 2015-10-07 | Co-Founder, CEO & Chairman Dr. Neal S. Walker D.O., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.aclaristx.com |
Full time employees 61 | Website https://www.aclaristx.com | ||
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.